Kumar Nikhil, Singh Mithalesh Kumar, Singh Lata, Jha Jayanti, Pushker Neelam, Lomi Neiwete, Meel Rachna, Sen Seema, Kashyap Seema
Ocular Pathology, All India Institute of Medical Sciences, New Delhi, India.
Dermatology, University of California, Irvine, California, USA
Br J Ophthalmol. 2025 Apr 21. doi: 10.1136/bjo-2024-325886.
Increased pigmentation has been associated with cancer stem-cell-like behaviour and chemoresistance in uveal melanoma (UM) and cutaneous melanoma. Therefore, our present study determines the correlation between pigmentation and cancer stem cell markers in UM patients.
Expression of PAX3, CD133, ABCG2, TRYP1, TRYP2 and microphthalmia-associated transcription factor (MITF) was assessed by immunohistochemistry along with mRNA expression level of PAX3 using quantitative real-time PCR in 70 prospective UM cases. Kaplan-Meier analysis and Cox-proportional hazards model were used to analyse the correlation of protein expression with clinicopathological parameters and patient outcome.
We found significant expression of PAX3, CD133 and ABCG2 proteins in 28/70 (40%), 34/70 (49%) and 31/70 (44%) cases, respectively. There was a positive correlation between nuclear expression of PAX3 and high-risk clinicopathological parameters such as necrosis and scleral invasion (p<0.01). CD133 and ABCG2 expression were positively correlated with distant metastasis (p=0.03 and 0.01). Immunoexpression of PAX3, CD133 and ABCG2 proteins was positively correlated with MITF. TYRP2 expression correlated with PAX3 and ABCG2 immunoexpression. Tumour pigmentation was not correlated with any of the markers. PAX3 mRNA expression was positively correlated with immunoexpression of CD133 (p<0.01), ABCG2 (p=0.01) and distant metastasis (p<0.01). On Kaplan-Meier survival analysis, reduced metastasis-free survival was observed in patients with tumours showing high CD133 and ABCG2 expression. No significant correlation was observed between tumour pigmentation and overall survival.
Our study highlights the association between PAX3 expression, pigmentation markers such as MITF and TRYP2 and cancer stem-cell markers in UM progression.
色素沉着增加与葡萄膜黑色素瘤(UM)和皮肤黑色素瘤中的癌症干细胞样行为及化疗耐药性有关。因此,我们目前的研究确定UM患者色素沉着与癌症干细胞标志物之间的相关性。
采用免疫组织化学方法评估70例前瞻性UM病例中PAX3、CD133、ABCG2、TRYP1、TRYP2和小眼相关转录因子(MITF)的表达,并使用定量实时PCR评估PAX3的mRNA表达水平。采用Kaplan-Meier分析和Cox比例风险模型分析蛋白表达与临床病理参数及患者预后的相关性。
我们发现PAX3、CD133和ABCG2蛋白在28/70(40%)、34/70(49%)和31/70(44%)的病例中分别有显著表达。PAX3的核表达与坏死和巩膜侵犯等高风险临床病理参数之间存在正相关(p<;0.01)。CD133和ABCG2表达与远处转移呈正相关(p=0.03和0.01)。PAX3、CD133和ABCG2蛋白的免疫表达与MITF呈正相关。TYRP2表达与PAX3和ABCG2免疫表达相关。肿瘤色素沉着与任何标志物均无相关性。PAX3 mRNA表达与CD133(p<;0.01)、ABCG2(p=0.01)的免疫表达及远处转移(p<;0.01)呈正相关。在Kaplan-Meier生存分析中,CD133和ABCG2表达高的肿瘤患者的无转移生存期缩短。未观察到肿瘤色素沉着与总生存期之间存在显著相关性。
我们的研究强调了PAX3表达、MITF和TRYP2等色素沉着标志物与UM进展中的癌症干细胞标志物之间的关联。